Kyrgyzstan vs Switzerland: HIV/AIDS deaths averted by antiretroviral therapy
HIV/AIDS deaths averted by antiretroviral therapy over time
- Kyrgyzstan
- Switzerland
How they compare
Kyrgyzstan currently reports 473.11 deaths against 398.9 deaths in Switzerland, a difference of 74.21 deaths.
That makes Kyrgyzstan's figure about 1.2 times Switzerland's.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Switzerland ahead.
Kyrgyzstan ranks 95th and Switzerland ranks 96th of 157 countries.
Across the 4 decades both report, Kyrgyzstan averaged higher in 1 and Switzerland in 3.
Head to head by decade
| Decade | Kyrgyzstan | Switzerland | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 136.75 deaths | 136.75 deaths | Switzerland |
| 2000s | 6.55 deaths | 599.76 deaths | 593.21 deaths | Switzerland |
| 2010s | 186.13 deaths | 490.23 deaths | 304.1 deaths | Switzerland |
| 2020s | 412.22 deaths | 411.15 deaths | 1.08 deaths | Kyrgyzstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Kyrgyzstan or Switzerland?
- Kyrgyzstan, at 473.11 deaths against 398.9 deaths in Switzerland as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Kyrgyzstan and Switzerland?
- 74.21 deaths, with Kyrgyzstan ahead.
- How many years of comparable data are there for Kyrgyzstan and Switzerland?
- 35 years are reported by both, from 1990 to 2024.
- How do Kyrgyzstan and Switzerland rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Kyrgyzstan ranks 95th and Switzerland ranks 96th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.